Neuphoria Therapeutics Inc. NEUP
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.47% | -21.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 64.16% | -64.73% | |||
| Operating Income | 77.77% | 64.73% | |||
| Income Before Tax | -814.84% | -129.51% | |||
| Income Tax Expenses | 0.00% | 0.00% | |||
| Earnings from Continuing Operations | -871.00% | -127.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -871.00% | -127.10% | |||
| EBIT | 77.77% | 64.73% | |||
| EBITDA | 97.25% | 69.65% | |||
| EPS Basic | -872.13% | -122.71% | |||
| Normalized Basic EPS | -202.78% | -113.61% | |||
| EPS Diluted | -872.13% | 87.96% | |||
| Normalized Diluted EPS | -202.78% | -113.61% | |||
| Average Basic Shares Outstanding | -0.07% | 19.29% | |||
| Average Diluted Shares Outstanding | -0.07% | 19.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||